- Research article
- Open Access
PI3K and PKC contribute to membrane depolarization mediated by α2-adrenoceptors in the canine isolated mesenteric vein
© Yamboliev and Mutafova-Yambolieva; licensee BioMed Central Ltd. 2005
- Received: 09 October 2004
- Accepted: 15 June 2005
- Published: 15 June 2005
Norepinephrine (NE), a classic neurotransmitter in the sympathetic nervous system, induces vasoconstriction of canine isolated mesenteric vein that is accompanied by a sustained membrane depolarization. The mechanisms underlying the NE-elicited membrane depolarization remain undefined. In the present study we hypothesized that phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) are involved in the electrical field stimulation (EFS)-induced slow membrane depolarization (SMD) in canine isolated mesenteric vein. EFS (0.1–2 Hz, 0.1 ms, 15V, 10 s)-induced changes in the membrane potential were recorded with a conventional intracellular microelectrode technique and evaluated in the absence and presence of inhibitors of neuronal activity, α-adrenoceptors, membrane ion channels, PI3K, inositol 1,4,5-triphosphate (InsP3) receptors, and PKC. Activation of PI3Kγ and PKCζ in response to exogenous NE and clonidine in the absence and presence of receptor and kinase inhibitors were also determined.
Contractile responses to NE and clonidine (0.05 – 10 μM) were significantly diminished in the presence of yohimbine (0.1 μM). Exogenous NE (0.1 μM) and clonidine (1 μM) elicited SMD. The resting membrane potential of canine mesenteric vein smooth muscle cells was -68.8 ± 0.8 mV. EFS elicited a biphasic depolarization comprised of excitatory junction potentials and SMD that are purinergic and adrenergic in nature, respectively. The magnitude of the SMD in response to EFS at 0.5 Hz was 9.4 ± 0.7 mV. This response was reduced by 65–98% by the fast Na+ channel inhibitor tetrodotoxin (1 μM), by the inhibitor of N-type Ca2+ channels ω-conotoxin GVIA (5 nM), the non-selective α-adrenoceptor blocker phentolamine (1 μM), the selective α2-adrenoceptor blocker yohimbine (0.1 μM), the ion channel inhibitors niflumic acid (NFA, 100 μM), 5-nitro-2-(3-phenylpropylamino) benzoic acid (NPPB, 30 μM), 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS, 200 μM), and Gd3+ (30 μM), and the PI3K inhibitors wortmannin (100 nM) and LY-294002 (10 μM). The SMD remained unchanged in the presence of the L-type Ca2+ channel blocker nicardipine (1 μM) and the InsP3 receptor blockers 2-aminoethoxydiphenylborate (2APB, 50 μM) and xestospongin C (3 μM). The inhibitor of PKC chelerythrine (1 μM), but not calphostin C (10 μM), diminished the SMD. Exogenous NE and clonidine (1 μM each) activated both PI3Kγ and PKCζ, and the activation of these kinases was abolished by preincubation of tissue with the α2-adrenoceptor blocker yohimbine.
Neuronally-released NE stimulates smooth muscle α2-adrenoceptors and activates PI3K and atypical PKC in the canine mesenteric vein. Events downstream of PKC lead to SMD and vasoconstriction. This represents a novel pathway for NE-induced membrane depolarization in a vascular smooth muscle preparation.
- Contractile Response
- Electrical Field Stimulation
Norepinephrine (NE), a classic neurotransmitter in the sympathetic nervous system, is released from adrenergic varicosities of stimulated postganglionic nerve terminals, activates postjunctional α-adrenoceptors and gives rise to a slow membrane depolarization (SMD) and contraction [1, 29]. The NE-induced SMD represents an important mechanism of excitation-contraction coupling in blood vessels however the signaling pathways underlying the NE-elicited SMD in vascular smooth muscle remain undefined.
One well-documented pathway downstream of activated G-protein coupled receptors (GPCRs) includes dissociation of Gαβγ trimers and production of Gα monomer and Gβγ dimer, and involvement of the latter proteins in signal transduction events downstream of α-adrenoceptors. For example, Gα mediates activation of phospholipase C (PLC), hydrolysis of phosphatidylinositol 4,5-bisphosphate (PI4,5P2), and generation of second messengers including inositol 1,4,5-triphosphate (InsP3) and diacylglycerol, DAG . These second messengers then mediate signal transduction events leading to activation of ion channels. InsP3 has the capacity to release cytosolic Ca2+ from intracellular stores, which then activates Ca2+-activated Cl- channels (ClCCa) and membrane depolarization, required for opening of voltage-operated calcium channels (VOCC) and Ca2+ influx. DAG, on the other hand, activates non-selective cation channels (NSCC) in rabbit portal vein . In addition, it becomes increasingly clear that Gβγ dimers can initiate intracellular signal transduction events as well. Phosphatidylinositol 3-kinase-γ (PI3Kγ), a member of class IB PI3Ks, was identified as a major effector of Gβγ in various cell and tissue preparations [13, 18]. Lipid products of the PI3Ks, phosphatidylinositol 3,4-bisphosphate (PI3,4P2) and phosphatidylinositol 3,4,5-trisphosphate (PI3,4,5P3), function as second messengers and can directly affect the activity of the membrane ion channels CFTR  and voltage-gated potassium channels . Alternatively, PI3,4P2 and PI3,4,5P3 can modulate membrane ion channels via activation of PKC isozymes [6, 25]. For example, Gβγ, PI3Kγ, and atypical PKC were shown to link activation of G-protein coupled M2-muscarinic receptors to metabotropic Ca2+ and voltage-independent Cl- channels in Xenopus oocytes . It was also demonstrated that PI3K mediates activation of L-type Ca2+ channels upon stimulation of M2-muscarinic receptors in rabbit portal vein myocytes  and α2-adrenoceptor induced vasoconstriction in porcine palmar lateral vein . These studies imply that activation of GPCRs could activate membrane ion channels and SMD via PI3K-dependent mechanisms. To our knowledge, however, coupling of α-adrenoceptors to PI3Kγ and membrane depolarization in vascular smooth muscles has not yet been reported.
We used canine isolated mesenteric vein to test the hypothesis that EFS-induced SMD is mediated by PI3K and PKC. Our results demonstrate both nerve stimulation and exogenous NE-mediated activation of α2-adrenoceptors, PI3K and PKC, and suggest a role for these kinases for the activation of membrane ion channels (e.g., ClCCa and/or NSCC) and development of SMD.
α2-Adrenoceptors mediate vasoconstriction and membrane depolarization in canine isolated mesenteric vein
EFS gives rise to a biphasic membrane depolarization
The EFS-induced slow membrane depolarization is sensitive to NFA, NPPB, DIDS and Gd3+
InsP3 receptors are not required for the EFS-elicited slow depolarization
PI3K blockers reduce the EFS-elicited slow depolarization
Exogenous NE and clonidine activate PI3Ks
As shown in Fig. 1 and Fig 3, incubation of veins with yohimbine significantly reduced both the NE-induced and clonidine-induced contractions as well as the SMD elicited by EFS. These observations raise the possibility that the EFS and exogenous NE-induced activation of PI3Ks may be mediated by α2-adrenoceptors. To test this possibility, we assayed phosphorylation of Akt (Fig. 7C) in tissues incubated with clonidine (1 μM, 3 min) in the absence or presence of yohimbine (0.1 μM, 1 h). Clonidine alone increased phosphorylation of Akt to 2.3-fold the basal phosphorylation and this increase was abolished by inhibition of α2-adrenoceptors with yohimbine and by inhibition of PI3Ks with LY-294002. These data indicate that α2-adrenoceptors are coupled to PI3Ks and their downstream target Akt.
Previous experiments have shown that PI3Kγ mediates signaling downstream of GPCRs [18, 33]. To test whether NE activates PI3Kγ, we incubated mesenteric vein with exogenous NE, then immunoprecipitated PI3Kγ and used the immunoprecipitated kinase to phosphorylate phosphatidylinositol (PI) in vitro. As shown in Fig. 7B, stimulation with NE increased the amount of PI3P (reaction product), suggesting that NE activated PI3Kγ. NE-mediated phosphorylation of PI was reversed in strips preincubated with LY-294002, indicating that it was a PI3K-dependent event. To test whether α2-adrenoceptors are linked to activation of PI3Kγ, we analyzed the activation of PI3Kγ in veins incubated with clonidine (1 μM) in the absence or presence of yohimbine (0.1 μM). As shown in Fig. 7D, clonidine activated PI3Kγ to 1.8-fold the basal, while yohimbine eliminated this activation. Thus, the activation of PI3Ks, and more specifically PI3Kγ, by exogenous NE and clonidine suggests that α2-adrenoceptors are coupled to PI3Kγ via activation of G-proteins.
Stimulation of atypical PKC(s) contributes to the EFS-elicited SMD
Exogenous NE and clonidine activate PKCζ
Ion channel blockers and PI3K blockers do not inhibit release of NE
Reduction of the SMD could be the result of suppressed NE release from sympathetic nerve terminals in veins, incubated with protein kinase and ion channel blockers. To test this possibility, we assayed the EFS-evoked release of NE in superfusates collected during EFS in control veins and in tissues preincubated with each of the aforementioned blockers. The average EFS -evoked overflow of NE in tissue controls (16 Hz, 0.1 ms) was 122 ± 27 fmol/mg (n = 17). In preincubated tissues, the overflow of NE changed to (fmol/mg tissue) 236 ± 40 in the presence of NFA (n = 6), 480 ± 122 by NPPB (n = 6), 142 ± 2 by DIDS (n = 6), 144 ± 5 by wortmannin (n = 5), and 214 ± 38 by LY-294002 (n = 7). Therefore, none of these agents reduced the EFS-evoked overflow of NE, indicating that their effects on the EFS-induced SMD are not due to inhibited NE release but to activation of postjunctional (i.e., smooth muscle) mechanisms.
The NE-induced membrane depolarization is an essential requirement for opening VOCC, Ca2+ entry and smooth muscle contraction, and hence it represents an important mechanism of autonomic neurovascular control. Previous studies  as well as the present work indicate that α2-adrenoceptors are involved in the SMD and the vasoconstriction of mesenteric vein. However, the downstream mechanisms that couple α2-adronoceptors to SMD remain undefined. For example, NE-induced activation of ClCCa plays a key role in the associated vasoconstriction and presumed membrane depolarization in various vascular networks [11, 16], but NSCC may also participate in the NE-induced vasoconstriction . In the present study, we have expanded upon these previous works by directly measuring membrane potential in response to EFS of intact canine isolated mesenteric veins. We found that the SMD in response to EFS is frequency-dependent, and is sensitive to the fast Na+ channel blocker TTX, to the inhibitor of neuronal N-type Ca2+ channels ω-conotoxin GVIA , and to the selective antagonist of α2-adrenoceptors yohimbine. Consistent with previous works, therefore, our results indicate that EFS gives rise to a SMD, which is mediated by smooth muscle α2-adrenoceptors and hence is primarily mediated by NE, released upon action potential. Furthermore, the SMD of the vascular smooth muscle cell membrane appears to be mediated by channels sensitive to NFA, NPPB, and DIDS. Although these inhibitors target transporters with presumed high preference for Cl- , they may also affect other ion channels, such as the inhibition of NSCC by DIDS . Because incubation of mesenteric veins with the NSCC blocker Gd3+ partially reduced the EFS-evoked SMD, our results suggest that activation of NSCC may indeed contribute to the EFS-elicited SMD in this blood vessel. None of the channel blockers reduced the release of NE thus demonstrating that the decrease of SMD is mediated by postjunctional smooth muscle mechanisms. The EFS-induced SMD remained unaffected by the InsP3 receptor inhibitors 2APB and xestospongin C, ruling out a substantial role of InsP3 receptor-mediated Ca2+ release in this response. Therefore, smooth muscle cell chloride channels and/or NCSS appear to be the primary activities that mediate the SMD in the canine mesenteric vein.
Furthermore, we identified a novel signal transduction mechanism governing the slow membrane depolarization, which involves enzymes of the PKC family. First, we used two PKC inhibitors with distinct PKC isozymes selectivity. Chelerythrine, for example, acts on the conserved catalytic domain of PKC as a competitive inhibitor with respect to the phosphate acceptor and a non-competitive inhibitor with respect to ATP . Therefore, chelerythrine can inhibit PKCs of all classes and effects mediated by them, including the slow depolarization in mesenteric veins. In contrast, calphostin C interacts with the regulatory domain of PKC by competing for the binding site of diacylglycerol and phorbol esters, but not Ca2+ and phospholipids. Thus, calphostin C is more specific inhibitor for classical and novel, and less specific for atypical PKC [9, 32]. In the present study, chelerythrine reduced, while calphostin C had no effect on the SMD. The lack of effect of calphostin C indicates that the EFS-induced membrane depolarization is most likely mediated by atypical PKC(s). We provided experimental support of this possibility by showing a distinct activation of the atypical PKCζ in mesenteric veins incubated with exogenous NE and clonidine. Although further studies are needed to identify the precise PKC isoform(s) contributing to the α2-adrenoceptor mediated SMD, the present study clearly suggests a PKC isozyme-specific regulation of the EFS- (and hence NE-) induced slow membrane depolarization in canine mesenteric vein.
The observation that atypical PKCs are involved in the SMC allowed us to speculate about the identity of some specific signaling molecules that function upstream of PKCζ, and could mediate the SMD as well. PI3Ks, and particularly PI3Kγ, was an obvious candidate for several reasons. Firstly, PI3Kγ is essential for activation of various ion transporters including L-type Ca2+ channels  and metabotropic nonselective cation channels . Secondly, PI3Kγ activates the phosphoinositide-dependent protein kinase 1 (PDK1), and although the latter can modulate classical (α and βI) and novel (δ and ε) PKC isoform, activation of atypical (ζ/λ/τ) PKCs, and particularly PKCζ, is a highly specific event downstream of PI3Kγ-PDK1 . We experimentally supported the hypothesized role of PI3Ks by showing that the PI3K inhibitors wortmannin and LY-294002 prevent the NE and clonidine-dependent activation of PKCζ and the SMD. These data are consistent with a role of PI3K in the regulation of voltage-independent Cl- channels, as well. PI3Kγ in particular is activated by Gβγ dimers, which are released upon dissociation of Gαβγ complexes following activation of GPCRs . Our experimental data demonstrate activation of PI3Kγ in veins incubated with the G-protein coupled α2-adrenoceptor agonists NE and clonidine. Furthermore, since the NE and clonidine-mediated activation of PI3Kγ, PKCζ and of the SMD was prevented by yohimbine, our results demonstrate that activation of α2-adrenoceptors is required for activation of PI3Kγ and PKCζ, and possibly for activation of membrane Cl- and/or NCSS channels and SMD in canine mesenteric vein. While the molecular identity of the membrane ion channels involved in these effects is presently elusive, our electrophysiological and biochemical data provide support to the possibility that activation of α2-adrenoceptors, PI3K and atypical PKC (possibly PKCζ) is essential for the regulation of the autonomic nervous system and vascular smooth muscle tone.
In this study we provide functional and biochemical evidence that NE, released from postganglionic nerve terminals, activates postjunctional α2-adrenoceptors, PI3Ks and atypical PKCs in canine isolated mesenteric vein. Our results further suggest that specific isoforms of the PI3K and PKC families, i.e. PI3Kγ and PKCζ respectively, may participate in the signal transduction pathway that couples α2-adrenoceptors to membrane ion channels. This signal transduction pathway mediates slow membrane depolarization and vasoconstriction of canine mesenteric vein.
Seventy-four mongrel dogs of either sex (averaging 15 kg) were obtained from vendors licensed by the United States Department of Agriculture. The use of dogs was approved by the University of Nevada's Animal Care and Use Committee. The animals were sacrificed with an overdose of pentobarbitone sodium (100 mg/kg intravenously), as recommended by the Panel on Euthanasia of the American Veterinary Medical Association. Experiments were conducted with second and third order branches of the inferior mesenteric vein (0.7–1.2 mm in diameter), dissected and denuded of endothelium as outlined previously .
Intracellular recording of membrane potential
Ring segments (7–10 mm long; 700–800 μM external diameter) were pinned out on the sylgard bottom of a 2 ml recording chamber perfused with Krebs solution (3 ml/min; 37°C; aerated with 95% O2/5% CO2) with the following composition (mM): 150 NaCl, 4.6 KCl, 1.2 MgCl2, 2.5 CaCl2, 24.8 NaHCO3, 1.2 KH2PO4 and 5.6 dextrose. Intracellular measurements were made through the adventitia of the vessel with fiber-containing borosilicate electrodes filled with 3 M KCl (70–100 MΩ resistance), as described previously . EFS at supramaximal voltage with trains of square-wave pulses (0.1 ms pulse width) was applied at 0.1–2 Hz for 10 s by means of two parallel platinum electrodes on both sides of the vessel connected to a Grass S48 stimulator. Once well-defined and reproducible slow depolarizations were obtained, various drugs were applied to the superfusion solution according to the experimental protocol. The maximum depolarization was evaluated.
The effects of NFA (100 μM), NPPB (30 μM), DIDS (200 μM), 2 APB (50 μM), and xestospongin C (3 μM) were examined by recording membrane potential in response to EFS before and 30-min after the tissue was superfused with the drug. To assess the role of PI3K and PKC or the NSCC, tissues were superfused with wortmannin (100 nM), LY 294002 (10 μM), chelerythrine (1 μM), calphostin C (10 μM) or Gd3+ (30 μM) for 60 min prior to the EFS. To produce appropriate time controls, EFS-mediated SMD were recorded periodically for 2–4 h in tissues not incubated with inhibitors. In some experiments tissues were perfused with NE (100 nM) for 30 s to induce SMD and changes in this response were monitored in the absence and presence of wortmannin (100 nM). In some experiments tissues were perfused with clonidine (1 μM) and changes in the membrane potential were monitored.
Transmitter release experiments and HPLC assay of NE
Segments of endothelium-denuded mesenteric veins (52.5 ± 3.2 mg wet weight, n = 30) were placed in 200-μl BRANDEL superfusion chambers as previously described . After 45 min equilibration, the tissues were subjected to a 30-seconds "conditioning" stimulation with a train of square wave pulses of 0.3 ms duration and a frequency of 4 Hz. Thirty minutes later the blood vessels were subjected to EFS for 60 s with a train of suprathreshold pulses of 0.1 ms duration at 16 Hz. Samples of the superfusion solution were collected before the electrical stimulation (resting overflow) and during the electrical stimulation (electrically evoked overflow) in ice-cold test tubes. Samples were analyzed for NE content by high performance liquid chromatography (HPLC) technique in conjunction with electrochemical detection .
After the equilibration period the tissues were superfused either with wortmannin (100 nM), or LY-294002 (10 μM), or chelerythrine (1 μM), or calphostin C (10 μM) for 60 min prior to EFS. In some experiments tissues were superfused with NFA (100 μM), NPPB (30 μM), or DIDS (200 μM) for 30 min prior to EFS. Only one drug was tested in each tissue.
Ring preparations (3 mm long) were mounted in 3 ml organ baths by inserting two stainless steel triangle mounts into the lumen, and force displacements were further investigated as described previously . The baths contained Krebs solution, which routinely contained indomethacin (1 μM) and Nω-nitro-L-arginine (l-NNA, 100 μM) to block potential residual effects of the endothelium and to eliminate possible time dependent effects due to activation of inducible nitric oxide synthase (iNOS) and/or cyclooxygenase. Thus, the contractile responses to KCl and nerve stimulation were reproducible over many hours when these blockers were included in the bathing solution. A resting force of 0.5 g was applied to the vein segments. This was found to stretch vessels to near the optimum length for tension development. After equilibrating the tissues , concentration-response relationships were obtained by cumulative addition of increasing concentrations of the α1-adrenoceptor agonist methoxamine in the absence and presence of 2APB (50 μM, 30 min pretreatment). Contractile responses elicited by methoxamine, NE and clonidine were expressed as a percentage of the contractile response produced with 70 mM KCl. The 70 mM KCl solution had the following composition (mM): 84.6 NaCl, 70 KCl, 1.2 MgCl2, 2.5 CaCl2, 24.8 NaHCO3, 1.2 KH2PO4 and 5.6 dextrose. Control experiments were carried out to determine the consistency of the contractile response to repeated applications of KCl (70 mM) over the duration of an average treatment protocol. The relative potency of methoxamine was determined by the concentration producing half-maximal effect. In some experiments, the effect of KCl (70 mM) was tested in the presence of nicardipine (1 μM). In other experiments, tissues were contracted with phorbol 12-myristate 13-acetate (PMA, 100 nM) in the absence or presence of chelerythrine (1 μM) or calphostin C (10 μM). In some experiments contractile responses to either exogenous NE or clonidine (both 0.05–10 μM) were monitored in the absence or presence of yohimbine (0.1 μM for 30 min).
Preparation of tissue homogenates and cytosolic fractions
Total protein extracts were prepared by glass-glass homogenization of mesenteric veins, pulverized under liquid nitrogen, with a buffer composed of (mM): 10 Tris-HCl (pH 7.4), 5 EDTA, 5 EGTA, 10 sodium pyrophosphate, 10 NaF, 1 sodium orthovanadate, 0.1 AEBSF and 0.001 leupeptin. Insoluble material was pelleted by centrifugation at 3,000 g (S3 supernatants) for 5 min at 4°C. S3 supernatants were transferred into clean tubes and centrifuged at 120,000 g for 60 min at 4°C to obtain S120 supernatants, which were used for assay of PI3K and PKC activity.
PI3K activation assay
Activation of PI3K was assayed by the phosphorylation of the downstream protein kinase Akt. Equal amounts of total supernatant protein (30 μg) were resolved by SDS-PAGE, transferred onto nitrocellulose membranes, and total and phospho-Ser473-Akt were assayed by immunoblotting, using a rabbit polyclonal or mouse monoclonal antibodies, respectively. Blots were scanned to obtain images and the immunoreactive bands were analyzed by densitometry, using the Quantity One software (BioRad). Changes in protein phosphorylation were calculated by normalizing the band density phospho-Akt to total Akt, and then were presented relative to the untreated group controls.
PI3Kγ activation assay
PI3Kγ was immunoprecipitated from S120 supernatants with a mouse monoclonal antibody, immobilized on Protein A/G agarose plus beads (Santa Cruz Biotechnology, Inc.). Kinase activity was assayed by phosphorylation of phosphatidylinositol (PI) in vitro, as described previously .
PKCζ activation assay
PKCζ activation was assayed by in vitro phosphorylation of a synthetic peptide substrate (PKCζPS), ERMRPRKRQGSVRRRV . S120 fractions from control and treated tissues were used as enzyme sources. The phosphorylation reactions were stopped by cooling on ice, and 10 μl reactions were spotted on P81 filter strips. Excess radioactivity was removed from the filters by 3 washes with 75 mM ortho-phosphoric acid and a final wash with ethanol. The filters were air-dried prior to radiography and spots were quantified by densitometry, using a BioRad Model 525 Molecular Imager. In order to verify PKCζ-specific phosphorylation of the substrate, in some phosphorylation reactions we added a specific myristoylated PKCζ peptide inhibitor (PKCζI, 50 μM, Calbiochem).
NFA, NPPB, wortmannin, LY 294002, DIDS, nicardipine, norepinephrine hydrochloride, tetrodotoxin, phentolamine, xestospongin C, gadolinium chloride, PMA (Sigma-Aldrich), 2 APB (Tocris), PKCζPS and PKCζI (Calbiochem), chelerythrine, calphostin C (Biomol), general and phospho-specific anti-Akt antibodies (Cell Signaling Technology, Inc.), phosphatidylinositol (PI, Avanti). Gadolinium solutions were prepared fresh each day, essentially as described elsewhere . Wortmannin, LY-294002, chelerythrine, calphostin C, PMA were dissolved in dimethylsulfoxide (DMSO) and diluted in double distilled water or Krebs solution. The final concentration of DMSO was less than 0.1 % DMSO.
Data are presented as means ± SEM. Means were compared by analysis of variance (one-way ANOVA) (GraphPadPrism v. 3, GraphPad Software, Inc.). A probability value of less than 0.05 was considered significant. In the intracellular recording and mechanical response experiments, n refers to the number of rings, and hence dogs, included in each experimental group.
This work was supported by NCRR grant P 20RR 15581 to IAY and US Public Service Grant HL60031 to VM-Y.
- Bulbring E, Tomita T: Catecholamine action on smooth muscle. Pharmacol Rev. 1987, 39: 49-96.PubMedGoogle Scholar
- Bultmann R, Starke K: Blockade by 4,4'-diisothiocyanatostilbene-2,2'-disulphonate (DIDS) of P2X-purinoceptors in rat vas deferens. Br J Pharmacol. 1994, 112: 690-694.PubMed CentralView ArticlePubMedGoogle Scholar
- Callaghan B, Koh SD, Keef KD: Muscarinic M2 Receptor Stimulation of Cav1.2b Requires Phosphatidylinositol 3-Kinase, Protein Kinase C, and c-Src. Circ Res. 2004, 94: 626-633. 10.1161/01.RES.0000118248.17466.B7.View ArticlePubMedGoogle Scholar
- Cheung DW: An electrophysiological study of alpha-adrenoceptor mediated excitation-contraction coupling in the smooth muscle cells of the rat saphenous vein. Br J Pharmacol. 1985, 84: 265-271.PubMed CentralPubMedGoogle Scholar
- Chou MM, Hou W, Johnson J, Graham LK, Lee MH, Chen CS, Newton AC, Schaffhausen BS, Toker A: Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr Biol. 1998, 8: 1069-1077. 10.1016/S0960-9822(98)70444-0.View ArticlePubMedGoogle Scholar
- Derman MP, Toker A, Hartwig JH, Spokes K, Falck JR, Chen CS, Cantley LC, Cantley LG: The lipid products of phosphoinositide 3-kinase increase cell motility through protein kinase C. J Biol Chem. 1997, 272: 6465-6470. 10.1074/jbc.272.10.6465.View ArticlePubMedGoogle Scholar
- Diakov A, Koch JP, Ducoudret O, Muller-Berger S, Fromter E: The disulfonic stilbene DIDS and the marine poison maitotoxin activate the same two types of endogenous cation conductance in the cell membrane of Xenopus laevis oocytes. Pflugers Arch. 2001, 442: 700-708. 10.1007/s004240100593.View ArticlePubMedGoogle Scholar
- Fuller CM, Ji HL, Tousson A, Elble RC, Pauli BU, Benos DJ: Ca(2+)-activated Cl(-) channels: a newly emerging anion transport family. Pflugers Arch. 2001, 443 (Suppl 1): S107-S110. 10.1007/s004240100655.View ArticlePubMedGoogle Scholar
- Gordge PC, Ryves WJ: Inhibitors of protein kinase C. Cellular Signalling. 1994, 6: 871-882. 10.1016/0898-6568(94)90020-5.View ArticlePubMedGoogle Scholar
- Hajduczok G, Chapleau MW, Ferlic RJ, Mao HZ, Abboud FM: Gadolinium inhibits mechanoelectrical transduction in rabbit carotid baroreceptors. Implication of stretch-activated channels. J Clin Invest. 1994, 94: 2392-2396.PubMed CentralView ArticlePubMedGoogle Scholar
- He Y, Tabrizchi R: Effects of niflumic acid on alpha1-adrenoceptor-induced vasoconstriction in mesenteric artery in vitro and in vivo in two-kidney one-clip hypertensive rats. Eur J Pharmacol. 1997, 328: 191-199. 10.1016/S0014-2999(97)83045-2.View ArticlePubMedGoogle Scholar
- Himmel B, Nagel G: Protein kinase-independent activation of CFTR by phosphatidylinositol phosphates. EMBO Rep. 2004, 5: 85-90. 10.1038/sj.embor.7400034.PubMed CentralView ArticlePubMedGoogle Scholar
- Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, Wymann MP: Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science. 2000, 287: 1049-1053. 10.1126/science.287.5455.1049.View ArticlePubMedGoogle Scholar
- Hottenstein OD, Kreulen DL: Comparison of the frequency dependence of venous and arterial responses to sympathetic nerve stimulation in guinea-pigs. J Physiol (Lond). 1987, 384: 153-167.View ArticleGoogle Scholar
- Kazanietz MG, Areces LB, Bahador A, Mischak H, Goodnight J, Mushinski JF, Blumberg PM: Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. Mol Pharmacol. 1993, 44: 298-307.PubMedGoogle Scholar
- Lamb FS, Barna TJ: Chloride ion currents contribute functionally to norepinephrine-induced vascular contraction. Am J Physiol. 1998, 275: H151-H160.PubMedGoogle Scholar
- Large WA: Receptor-operated Ca2(+)-permeable nonselective cation channels in vascular smooth muscle: a physiologic perspective. J Cardiovasc Electrophysiol. 2002, 13: 493-501. 10.1046/j.1540-8167.2002.00493.x.View ArticlePubMedGoogle Scholar
- Leopoldt D, Hanck T, Exner T, Maier U, Wetzker R, Nurnberg B: Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem. 1998, 273: 7024-7029. 10.1074/jbc.273.12.7024.View ArticlePubMedGoogle Scholar
- Loussouarn G, Park KH, Bellocq C, Baro I, Charpentier F, Escande D: Phosphatidylinositol-4,5-bisphosphate, PIP2, controls KCNQ1/KCNE1 voltage-gated potassium channels: a functional homology between voltage-gated and inward rectifier K+ channels. EMBO J. 2003, 22: 5412-5421. 10.1093/emboj/cdg526.PubMed CentralView ArticlePubMedGoogle Scholar
- Mironneau J, Macrez-Lepretre N: Modulation of Ca2+ channels by alpha 1A- and alpha 2A-adrenoceptors in vascular myocytes: involvement of different transduction pathways. Cell Signal. 1995, 7: 471-479. 10.1016/0898-6568(95)00014-G.View ArticlePubMedGoogle Scholar
- Mutafova-Yambolieva VN, Carolan BM, Harden TK, Keef KD: Multiple P2Y receptors mediate contraction in guinea pig mesenteric vein. Gen Pharmacol. 2000, 34: 127-136. 10.1016/S0306-3623(00)00054-9.View ArticlePubMedGoogle Scholar
- Mutafova-Yambolieva VN, Keef KD: Frequency dependent alpha(2)-adrenoceptor mediated modulation of excitatory junction potentials in guinea-pig mesenteric artery. Eur J Pharmacol. 2001, 411: 123-127. 10.1016/S0014-2999(00)00905-5.View ArticlePubMedGoogle Scholar
- Mutafova-Yambolieva VN, Smyth L, Bobalova J: Involvement of cyclic AMP-mediated pathway in neural release of noradrenaline in canine isolated mesenteric artery and vein. Cardiovasc Res. 2003, 57: 217-224. 10.1016/S0008-6363(02)00648-X.View ArticlePubMedGoogle Scholar
- Nielsen KJ, Schroeder T, Lewis R: Structure-activity relationships of omega-conotoxins at N-type voltage-sensitive calcium channels. J Mol Recognit. 2000, 13: 55-70. 10.1002/(SICI)1099-1352(200003/04)13:2<55::AID-JMR488>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
- Rameh LE, Cantley LC: The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem. 1999, 274: 8347-8350. 10.1074/jbc.274.13.8347.View ArticlePubMedGoogle Scholar
- Remillard CV, Lupien MA, Crepeau V, Leblanc N: Role of Ca2+- and swelling-activated Cl- channels in alpha1-adrenoceptor-mediated tone in pressurized rabbit mesenteric arterioles. Cardiovasc Res. 2000, 46: 557-568. 10.1016/S0008-6363(00)00021-3.View ArticlePubMedGoogle Scholar
- Roberts RE: Alpha 2 adrenoceptor-mediated vasoconstriction in porcine palmar lateral vein: role of phosphatidylinositol 3-kinase and EGF receptor transactivation. Br J Pharmacol. 2003, 138: 107-116. 10.1038/sj.bjp.0705014.PubMed CentralView ArticlePubMedGoogle Scholar
- Ron D, Kazanietz MG: New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J. 1999, 13: 1658-1676.PubMedGoogle Scholar
- Suzuki H: Adrenergic transmission in the dog mesenteric vein and its modulation by alpha-adrenoceptor antagonists. Br J Pharmacol. 1984, 81: 479-489.PubMed CentralView ArticlePubMedGoogle Scholar
- Viard P, Exner T, Maier U, Mironneau J, Nurnberg B, Macrez N: Gbetagamma dimers stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase. FASEB J. 1999, 13: 685-694.PubMedGoogle Scholar
- Wang YX, Dhulipala PD, Li L, Benovic JL, Kotlikoff MI: Coupling of M2 muscarinic receptors to membrane ion channels via phosphoinositide 3-kinase gamma and atypical protein kinase C. J Biol Chem. 1999, 274: 13859-13864. 10.1074/jbc.274.20.13859.View ArticlePubMedGoogle Scholar
- Way KJ, Chou E, King GL: Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci. 2000, 21: 181-187. 10.1016/S0165-6147(00)01468-1.View ArticlePubMedGoogle Scholar
- Wymann MP, Pirola L: Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta. 1998, 1436: 127-150.View ArticlePubMedGoogle Scholar
- Yamboliev IA, Wiesmann KM, Singer CA, Hedges JC, Gerthoffer WT: Phosphatidylinositol 3-kinases regulate ERK and p38 MAP kinases in canine colonic smooth muscle. Am J Physiol Cell Physiol. 2000, 279: C352-C360.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.